Volume 7, Issue 11: Emerging Disease-Modifying Therapies in Cystic Fibrosis

e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.

(Volume 7, Issue 11)

Target Audience

Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.

Learning Objectives

After participating in this activity, the participant will demonstrate the ability to: 

  • Summarize the potential side effects associated with CFTR modulators.
  • Explain the relationship between changes in sweat chloride and changes in lung function during CFTR modulator treatment.
  • Discuss the benefits observed in young patients with the F508del/F508del genotype treated with lumacaftor/ivacaftor.
Course summary
Available credit: 
  • 1.00 ANCC
  • 1.00 Attendance
Course opens: 
01/18/2018
Course expires: 
01/17/2020
Cost:
$0.00
John P. Clancy, MD
Professor, UC Department of
Pediatrics Gunnar
Esiason/Cincinnati Bell Chair
Research Director, Division of
Pulmonary Medicine Cincinnati
Children’s Hospital Medical Center
Cincinnati, Ohio

Available Credit

  • 1.00 ANCC
  • 1.00 Attendance

Accreditation Period

Course opens: 
01/18/2018
Course expires: 
01/17/2020

Price

Cost:
$0.00
Please login or register to take this course.